This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Diazepinomicin
- DrugBank Accession Number
- DB12420
- Background
-
Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C. Diazepinomicin is a natural product derived from a non-pathogenic micro-organism. Discovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and in vitro models.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
-
Structure for Diazepinomicin (DB12420)
- Weight
-
Average: 462.59
Monoisotopic: 462.251857583 - Chemical Formula
- C28H34N2O4
- Synonyms
-
- 4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo(b,e)(1,4)diazepin-11-one
- DIAZEPINOMICIN
- External IDs
-
- BU-4664L
- ECO-4601
- TLN-4601
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
-
Diazepinomicin demonstrates broad in vitro cytotoxic activity across a diverse panel of tumour cell lines and in vivo efficacy in a number of xenograft tumour models. Preclinical data suggest that diazepinomicin is a targeted anti-cancer agent with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR) and inhibition of the Ras-MAPK pathway.
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as dibenzodiazepines. These are compounds containing a dibenzodiazepine moiety, which consists of two benzene connected by diazepine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzodiazepines
- Sub Class
- Dibenzodiazepines
- Direct Parent
- Dibenzodiazepines
- Alternative Parents
- Sesquiterpenoids/1,4-benzodiazepines/1-hydroxy-4-unsubstituted benzenoids/1-hydroxy-2-unsubstituted benzenoids/1,4-diazepines/Primary aromatic amines/Vinylogous amides/Tertiary carboxylic acid amides/Lactams/Amino acids and derivatives show 5 more
- Substituents
- 1,4-benzodiazepine/1-hydroxy-2-unsubstituted benzenoid/1-hydroxy-4-unsubstituted benzenoid/Amine/Amino acid or derivatives/Aromatic heteropolycyclic compound/Azacycle/Benzenoid/Carboxamide group/Carboxylic acid derivative show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YPH994Y0RF
- CAS number
- 733035-26-2
- InChI Key
- SALVHVNECODMJP-GNUCVDFRSA-N
- InChI
-
InChI=1S/C28H34N2O4/c1-18(2)8-5-9-19(3)10-6-11-20(4)14-15-30-23-16-21(31)17-25(33)27(23)29-26-22(28(30)34)12-7-13-24(26)32/h7-8,10,12-14,16-17,29,31-33H,5-6,9,11,15H2,1-4H3/b19-10+,20-14+
- IUPAC Name
-
4,6,15-trihydroxy-9-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-2,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
- SMILES
-
CC(C)=CCC\C(C)=C\CC\C(C)=C\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=O
References
- 一般引用
-
- Gourdeau H, McAlpine JB, Ranger M, Simard B, Berger F, Beaudry F, Farnet CM, Falardeau P: Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. Cancer Chemother Pharmacol. 2008 May;61(6):911-21. Epub 2007 Jul 11. [Article]
- External Links
-
- PubChem Compound
- 9868980
- PubChem Substance
- 347828664
- ChemSpider
- 8044671
- BindingDB
- 50481798
- ChEBI
- 156321
- ChEMBL
- CHEMBL550961
- ZINC
- ZINC000003938687
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 2 Terminated Treatment High Grade Glioma: Glioblastoma (GBM) 1 1 Completed Treatment Breast Cancer/Colorectal Cancer/Glioma/Lung Cancer/Ovarian Cancer/Pancreatic Cancer/Prostate Cancer/Tumor 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 0.004 mg/mL ALOGPS logP 5.67 ALOGPS logP 7.47 Chemaxon logS -5.1 ALOGPS pKa (Strongest Acidic) 8.88 Chemaxon pKa (Strongest Basic) 0.73 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 93.03 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 139.8 m3·mol-1 Chemaxon Polarizability 53.25 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon 医学博士DR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 22:18 / Updated at December 01, 2022 11:27